Abstract
Objective
To observe the clinical effects of kanglaite (KLT) capsules combined with transcatheter arterial chemoembolization (TACE) in treating patients with mid or late-stage primary hepatocellular carcinoma (HCC).
Methods
Sixty-five cases were randomly divided into 2 groups, 32 patients in combination group received the treatment of KLT capsules + TACE and 33 patients in control group were treated with TACE alone. The objective response rate (RR), serum alpha fetoprotein (AFP), peripheral blood T lymphocyte subgroups (T-LS), quality of life (QOL), time to progression (TTP) and adverse reaction were observed and compared between 2 groups.
Results
The objective response rate and serum alpha fetoprotein levels had no significant difference between the two groups (P > 0.05). Combination group was superior to control group in quality of life (QOL), time to progression (TTP), peripheral blood T lymphocyte subgroups (CD3+, CD4+, CD4+∖CD8 ratio) and liver adverse reactions, with significant differences (P < 0.05).
Conclusion
KLT capsules combined with TACE is an effective method to treat primary hepatocellular carcinoma (HCC) patients who have lost the opportunity of surgical therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wu MC. Progress in the diagnosis and treatment of primary hepatocarcinoma. Chin Cancer (Chinese), 1999, 8: 18–20.
Tang ZX. The basic and clinical study on the metastasis & recurrence of hepatic carcinoma. Shanghai: Shanghai Scientific & Technical Press, 2003. 45–51.
Chen JG, Sankaranarayanan R, Shen ZC, et al. Population based cancer survival: an analysis of 16, 922 cases. Chin J Oncol (Chinese), 1998, 20: 202–206.
Sun JS, Chen GM, Long ZX, et al. Progress in the combined treatment of primary hepatocarcinoma. Chin J Clin Oncol Rehabil (Chinese), 2005, 12: 468–470.
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 2003, 37: 429–442.
Lau WY, Yu SC, Lai EC, et al. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg, 2006, 202: 155–168.
Luo DX. The immunostimulatory effects of kanglaite Injection. Shanxi Oncol Med (Chinese), 2002, 10: 145.
Jiang XL, Zhang L, Xu ZY. Effects of kanglaite Injection on angiogenesis. Tumor (Chinese), 2000, 20: 313–314.
Li Y, Shi TK. Mechanisms of kanglaite induced apoptosis in tumor cells. Chin J Clin Oncol (Chinese), 2002, 29: 869–873.
Liu JL, Ekomo B, Wei CY, et al. Apoptosis of human hepatocellular carcinoma cells induced by kanglaite. The Pract J Cancer (Chinese), 2001, 16: 343–344.
Zhu PS. Clinical study on treatment of advanced lung cancer by combined therapy of kanglaite and Chinese medicine differentiation of symptoms and signs. Am J Orient Med Res, 1998, 1: 97–98.
Shao ZJ, Qin SK, He ZM. Effects of kanglaite Injection on improving quality of life and analgesia of advanced tumor patients. J Pract Oncol (Chinese), 2000, 15: 59–60.
Qin YT, Wei CY, Li T. The effect of kanglaite Injection on immune function in patients with advanced primary hepatocarcinoma. J Cancer Prev Treat, 2001, 8: 23–24.
Tang DP, Wei CY, Tang K, et al. The experimental study of kanglaite Injection in hepatocarcinomatous cells. Chin J Cancer Prev Treat (Chinese), 2001, 8: 396–397.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, D., Xu, X., Bao, D. et al. Effects of kanglaite capsules combined with transcatheter arterial chemoembolization (TACE) on patients with mid or late-stage primary hepatocellular carcinoma (HCC). Chin. -Ger. J. Clin. Oncol. 8, 65–68 (2009). https://doi.org/10.1007/s10330-008-0142-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-008-0142-8